A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus

Current Medical Research and Opinion

Volumn 30, Issue 6, 2014, Pages 1095-1106

  Seino, Yutaka ^a   Inagaki, Nobuya ^b   Miyahara, Hajime ^c   Okuda, Inaha ^c   Bush, Mark ^d   Ye, June ^e   Claire Holland, M ^e   Johnson, Susan ^e   Lewis, Eric ^e   Nakajima, Hiromu ^c  

^a KANSAI ELECTRIC POWER CO   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c Development and Medical Affairs Division   (Japan)

^d Nuventra Pharma Sciences   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Albiglutide; Diabetes mellitus Type 2; Glucagon like peptide 1; Japanese

Indexed keywords

ALBIGLUTIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; ORAL ANTIDIABETIC AGENT; PLACEBO; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; ANTIDIABETIC ACTIVITY; ARTICLE; BRAIN INFARCTION; CAROTID ARTERY OBSTRUCTION; COLON CANCER; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DETERMINATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; HEARING IMPAIRMENT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INJECTION SITE REACTION; JAPANESE (PEOPLE); KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORGANIZING PNEUMONIA; OROPHARYNX PAIN; PHARMACODYNAMICS; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; STANDARDIZATION; TREATMENT DURATION; VERTIGO; VOMITING; ANALOGS AND DERIVATIVES; BLOOD; DIABETES MELLITUS, TYPE 2; FEMALE; JAPAN; MALE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84900818069     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.896327     Document Type: Article

References (32)

1. The global burden. Brussels, Belgium: International Diabetes Federation, 2012. Available at: http://www.idf.org/diabetesatlas/5e/the-global-burden [Last accessed 29 October 2013]
2. The World Health Report 2002. Geneva, Switzerland: World Health Organization, 2002. Available at: http://www.who.int/whr/2002/en/whr02-en.pdf [Last accessed 29 October 2013]
3. Outline for the Results of the National Health and Nutrition Survey Japan, 2007. Tokyo, Japan: Ministry of Health, Labour and Welfare, 2007. Available at: http://www.nih.go.jp/eiken/english/research/pdf/nhns2007.pdf [Last accessed 29 October 2013]
4. Fukushima M, Usami M, Ikeda M, et al. Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. Metabolism 2004;53:831-5
5. Katakura M, Komatsu M, Sato Y, et al. Primacy of beta-cell dysfunction in the development of hyperglycemia: a study in the Japanese general population. Metabolism 2004;53:949-53
6. Boffetta P, McLerran D, Chen Y, et al. Body mass index and diabetes in Asia: a cross-sectional pooled analysis of 900, 000 individuals in the Asia cohort consortium. PLoS One 2011;6:e19930
7. Treatment Guide for Diabetes, 2007. Tokyo, Japan: Japan Diabetes Society; 2007. Available at: http://www.jds.or.jp/modules/en/index.php?content- id35 [Last accessed 29 October 2013]
8. Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30
9. Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002;143:4397-408
10. Nauck MA, Wollschlager D, Werner J, et al. Effects of subcutaneous gluca-gon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996;39:1546-53
11. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig 2010;1:8-23
12. Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and gluca-gon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Investig 2013;4:108-30
13. Vilsboll T, Agerso H, Krarup T, et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003;88:220-4
14. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide his-tidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829-35
15. Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals Inc., 2011. Available at: http://documents.byetta.com/Byetta-PI.pdf [Last accessed 29 October 2013]
16. Victoza [package insert]. Plainsboro NJ: Novo Nordisk Inc. 2010. Available at: http://www.novo-pi.com/victoza.pdf [Last accessed 29 October 2013]
17. Yabe D, Kuroe A, Lee S, et al. Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: comparison of type 2 diabetes patients and healthy controls. J Diabetes Investig 2010;1:56-9
18. Rosenstock J, Stewart MW. Albiglutide. Glucagon-like peptide GLP-1 receptor agonist, treatment of type 2 diabetes. Drugs Future 2010;35:701-12
19. Rosenstock J, Reusch J, Bush M, et al. Potential of albiglutide, a long-Acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009;32:1880-6
20. Matthews JE, Stewart MW, De Boever EH, et al. Pharmacodynamics, pharma-cokinetics, safety, and tolerability of albiglutide, a long-Acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93:4810-17
21. Seino Y, Nakajima H, Miyahara H, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-Acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. Curr Med Res Opin 2009;25:3049-57
22. The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, Seino Y, Nanjo K, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig 2010; 1: 212-28
23. Li Y, Hansotia T, Yusta B, et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003;278:471-8
24. Monami M, Dicembrini I, Marchionni N, et al. Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-Analysis. Exp Diabetes Res 2012;2012:672658
25. Vilsboll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-Analyses of randomised controlled trials. BMJ 2012;344:d7771
26. Cabou C, Burcelin R. GLP-1, the gut-brain, and brain-periphery axes. Rev Diabet Stud 2011;8:418-31
27. Seino Y, Rasmussen MF, Nishida T, et al. Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: results of a 52-week, randomized, multicenter trial. J Diabetes Investig 2011;2:280-6
28. Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-Acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007;30:1608-10
29. Kanoski SE, Rupprecht LE, Fortin SM, et al. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide. Neuropharmacology 2012;62:1916-27
30. Knudsen LB, Madsen LW, Andersen S, et al. Glucagon-like pep-tide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010;151: 1473-86
31. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exena-tide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25:1019-27
32. Guidance for Industry. Diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Washington, DC: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 2008. Available at: http://www.fda.gov/ downloads/drugs/guidancecomplianceregulatoryinformation/guidance/ucm071627.pdf [Last accessed 29 October 2013]